Axonics, Inc. Forms 3, 4 and 5: Restricted Stock Units and Performance Rights
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 18 rows in 2024. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2024-11-15: Reporting owner Woock John; Form 4; Security Performance-Based Restricted Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2024-11-15: Reporting owner Sama Rinda; Form 4; Security Performance-Based Restricted Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2024-11-15: Reporting owner Noblett Karen; Form 4; Security Performance-Based Restricted Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2024-11-15: Reporting owner Keese Kari Leigh; Form 4; Security Performance-Based Restricted Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2024-11-15 | Woock John Officer (EVP, Chief Mktg/Strtgy Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −13,125 0 owned after | $0.00 | 2024-11-15 | |
| 2024-11-15 | Sama Rinda Officer (Chief Operating Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −13,125 0 owned after | $0.00 | 2024-11-15 | |
| 2024-11-15 | Noblett Karen Officer (Chief Medical Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,500 0 owned after | $0.00 | 2024-11-15 | |
| 2024-11-15 | Keese Kari Leigh Officer (Chief Financial Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −3,125 0 owned after | $0.00 | 2024-11-15 | |
| 2024-11-15 | Ford Alfred J Jr Officer (Chief Commercial Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −11,250 0 owned after | $0.00 | 2024-11-15 | |
| 2024-11-15 | COHEN RAYMOND W Director, Officer (Chief Executive Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −31,125 0 owned after | $0.00 | 2024-11-15 | |
| 2024-01-31 | Sama Rinda Officer (Chief Operating Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,500 0 owned after | $0.00 | 2024-02-02 | |
| 2024-01-31 | Sama Rinda Officer (Chief Operating Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −17,500 0 owned after | $0.00 | 2024-02-02 | |
| 2024-01-31 | Noblett Karen Officer (Chief Medical Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,500 0 owned after | $0.00 | 2024-02-02 | |
| 2024-01-31 | Noblett Karen Officer (Chief Medical Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 0 owned after | $0.00 | 2024-02-02 | |
| 2024-01-31 | Woock John Officer (EVP, Chief Mktg/Strtgy Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,500 0 owned after | $0.00 | 2024-02-02 | |
| 2024-01-31 | Woock John Officer (EVP, Chief Mktg/Strtgy Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −17,500 0 owned after | $0.00 | 2024-02-02 | |
| 2024-01-31 | Ford Alfred J Jr Officer (Chief Commercial Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,500 0 owned after | $0.00 | 2024-02-02 | |
| 2024-01-31 | Ford Alfred J Jr Officer (Chief Commercial Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 0 owned after | $0.00 | 2024-02-02 | |
| 2024-01-31 | Keese Kari Leigh Officer (Chief Financial Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,000 0 owned after | $0.00 | 2024-02-02 | |
| 2024-01-31 | Keese Kari Leigh Officer (Chief Financial Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,167 0 owned after | $0.00 | 2024-02-02 | |
| 2024-01-31 | COHEN RAYMOND W Director, Officer (Chief Executive Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −21,900 0 owned after | $0.00 | 2024-02-02 | |
| 2024-01-31 | COHEN RAYMOND W Director, Officer (Chief Executive Officer) | 4 | Performance-Based Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −41,500 0 owned after | $0.00 | 2024-02-02 |